Pfizer Sets New Biotech M&A Record
Pfizer's proposed acquisition of Rinat Neuroscience is the costliest private biotech purchase yet--it paid $500 million in cash for the CNS play. What's more extraordinary still is that the most valuable asset at Rinat is pre-clinical.
You may also be interested in...
With Twists And Turns, KaloBios Goes Public
It wasn’t pretty, but KaloBios Pharmaceuticals went public and raised $70 million in late January, the first IPO for a US antibody company in more than a decade.
Where Are They Now? Checking In With Four Alzheimer’s Disease Start-Ups
Four start-ups previously profiled in START-UP – CoMentis, EnVivo Pharmaceuticals, Avid Radiopharmaceuticals and AC Immune SA – show how some biotechs have successfully ridden through the rough patches any company brave enough to tackle Alzheimer’s disease will likely face.
Alzheimer's R&D: Tweaking Venture's Risk-Reward Ratio
Building Alzheimer's-focused companies remains difficult, in part because venture capital remains scarce. But advancese in diagnostic and imaging tools, improved means of measuring the impact of drugs on cognition, and a better understanding of therapeutic targets mean investment risks are improving, say some executives and VCs. Can Alzheimer's attract more mainstream VC investment and pay off with more lucrative deals like Pfizer's acquisition of Rinat?